Addition Therapeutics surfaced from stealth with a sizeable financing and a novel RNA‑mediated insertion platform. The startup raised $106.5M to advance its PRINT (Precise RNA‑Mediated Insertion of Transgenes) technology, which uses retrotransposase biology to insert genes from RNA delivered in lipid nanoparticles. The company says the approach can sidestep limitations of DNA‑based vectors and offers a potentially more scalable route to gene insertion therapies. Addition’s funding will support platform development, chip and delivery optimization, and strategic collaborations; the story signals continued investor appetite for alternatives to classical viral vectors in gene therapy.